The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Identifieur interne : 000137 ( PubMed/Checkpoint ); précédent : 000136; suivant : 000138The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.
Auteurs : Leon Caly [Australie] ; Julian D. Druce [Australie] ; Mike G. Catton [Australie] ; David A. Jans [Australie] ; Kylie M. Wagstaff [Australie]Source :
- Antiviral research [ 1872-9096 ] ; 2020.
Abstract
Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.
DOI: 10.1016/j.antiviral.2020.104787
PubMed: 32251768
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:32251768Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.</title>
<author><name sortKey="Caly, Leon" sort="Caly, Leon" uniqKey="Caly L" first="Leon" last="Caly">Leon Caly</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Druce, Julian D" sort="Druce, Julian D" uniqKey="Druce J" first="Julian D" last="Druce">Julian D. Druce</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Catton, Mike G" sort="Catton, Mike G" uniqKey="Catton M" first="Mike G" last="Catton">Mike G. Catton</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jans, David A" sort="Jans, David A" uniqKey="Jans D" first="David A" last="Jans">David A. Jans</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wagstaff, Kylie M" sort="Wagstaff, Kylie M" uniqKey="Wagstaff K" first="Kylie M" last="Wagstaff">Kylie M. Wagstaff</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia. Electronic address: kylie.wagstaff@monash.edu.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32251768</idno>
<idno type="pmid">32251768</idno>
<idno type="doi">10.1016/j.antiviral.2020.104787</idno>
<idno type="wicri:Area/PubMed/Corpus">000333</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000333</idno>
<idno type="wicri:Area/PubMed/Curation">000333</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000333</idno>
<idno type="wicri:Area/PubMed/Checkpoint">000137</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000137</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.</title>
<author><name sortKey="Caly, Leon" sort="Caly, Leon" uniqKey="Caly L" first="Leon" last="Caly">Leon Caly</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Druce, Julian D" sort="Druce, Julian D" uniqKey="Druce J" first="Julian D" last="Druce">Julian D. Druce</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Catton, Mike G" sort="Catton, Mike G" uniqKey="Catton M" first="Mike G" last="Catton">Mike G. Catton</name>
<affiliation wicri:level="1"><nlm:affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000</wicri:regionArea>
<wicri:noRegion>3000</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Jans, David A" sort="Jans, David A" uniqKey="Jans D" first="David A" last="Jans">David A. Jans</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wagstaff, Kylie M" sort="Wagstaff, Kylie M" uniqKey="Wagstaff K" first="Kylie M" last="Wagstaff">Kylie M. Wagstaff</name>
<affiliation wicri:level="1"><nlm:affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia. Electronic address: kylie.wagstaff@monash.edu.</nlm:affiliation>
<country xml:lang="fr">Australie</country>
<wicri:regionArea>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800</wicri:regionArea>
<wicri:noRegion>3800</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j">Antiviral research</title>
<idno type="eISSN">1872-9096</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32251768</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1872-9096</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>178</Volume>
<PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>03</Day>
</PubDate>
</JournalIssue>
<Title>Antiviral research</Title>
<ISOAbbreviation>Antiviral Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro.</ArticleTitle>
<Pagination><MedlinePgn>104787</MedlinePgn>
</Pagination>
<ELocationID EIdType="pii" ValidYN="Y">S0166-3542(20)30201-1</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.1016/j.antiviral.2020.104787</ELocationID>
<Abstract><AbstractText>Although several clinical trials are now underway to test possible therapies, the worldwide response to the COVID-19 outbreak has been largely limited to monitoring/containment. We report here that Ivermectin, an FDA-approved anti-parasitic previously shown to have broad-spectrum anti-viral activity in vitro, is an inhibitor of the causative virus (SARS-CoV-2), with a single addition to Vero-hSLAM cells 2 h post infection with SARS-CoV-2 able to effect ~5000-fold reduction in viral RNA at 48 h. Ivermectin therefore warrants further investigation for possible benefits in humans.</AbstractText>
<CopyrightInformation>Copyright © 2020 The Author(s). Published by Elsevier B.V. All rights reserved.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Caly</LastName>
<ForeName>Leon</ForeName>
<Initials>L</Initials>
<AffiliationInfo><Affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Druce</LastName>
<ForeName>Julian D</ForeName>
<Initials>JD</Initials>
<AffiliationInfo><Affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Catton</LastName>
<ForeName>Mike G</ForeName>
<Initials>MG</Initials>
<AffiliationInfo><Affiliation>Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital, At the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Jans</LastName>
<ForeName>David A</ForeName>
<Initials>DA</Initials>
<AffiliationInfo><Affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Wagstaff</LastName>
<ForeName>Kylie M</ForeName>
<Initials>KM</Initials>
<AffiliationInfo><Affiliation>Biomedicine Discovery Institute, Monash University, Clayton, Vic, 3800, Australia. Electronic address: kylie.wagstaff@monash.edu.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>03</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Antiviral Res</MedlineTA>
<NlmUniqueID>8109699</NlmUniqueID>
<ISSNLinking>0166-3542</ISSNLinking>
</MedlineJournalInfo>
<CitationSubset>IM</CitationSubset>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>03</Month>
<Day>27</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>03</Month>
<Day>29</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>7</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32251768</ArticleId>
<ArticleId IdType="pii">S0166-3542(20)30201-1</ArticleId>
<ArticleId IdType="doi">10.1016/j.antiviral.2020.104787</ArticleId>
<ArticleId IdType="pmc">PMC7129059</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Australie</li>
</country>
</list>
<tree><country name="Australie"><noRegion><name sortKey="Caly, Leon" sort="Caly, Leon" uniqKey="Caly L" first="Leon" last="Caly">Leon Caly</name>
</noRegion>
<name sortKey="Catton, Mike G" sort="Catton, Mike G" uniqKey="Catton M" first="Mike G" last="Catton">Mike G. Catton</name>
<name sortKey="Druce, Julian D" sort="Druce, Julian D" uniqKey="Druce J" first="Julian D" last="Druce">Julian D. Druce</name>
<name sortKey="Jans, David A" sort="Jans, David A" uniqKey="Jans D" first="David A" last="Jans">David A. Jans</name>
<name sortKey="Wagstaff, Kylie M" sort="Wagstaff, Kylie M" uniqKey="Wagstaff K" first="Kylie M" last="Wagstaff">Kylie M. Wagstaff</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000137 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000137 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= PubMed |étape= Checkpoint |type= RBID |clé= pubmed:32251768 |texte= The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:32251768" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a SrasV1
This area was generated with Dilib version V0.6.33. |